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Abstract 
The purpose of this study was to prepare polymeric microspheres containing Ketoprofen (KFN) by single 
emulsion [oil-in-water (o/w)] solvent evaporation method. Polycaprolactone (PCL), biocompatible polymer, 
was used for the preparation of sustained released microspheres of KFN. A Plackett–Burman design was 
employed by using the Design-Expert® software (Version- 9.0.3.1, Stat-Ease Inc., Minneapolis, MN). Eleven 
factors out of six processing factors were investigated in order to enhance the encapsulation efficiency (EE) 
of the microspheres. The resultant microspheres were characterized for their size, morphology, EE, and 
drug release. Imaging of particles was performed by field emission scanning electron microscopy. 
Interaction between the drug and polymers were investigated by Fourier transform infrared (FTIR) 
spectroscopy, X-ray powder diffractometry (XRPD) and Differential Scanning Calorimetry (DSC). Graphical 
and mathematical analyses of the design showed that concentration of factor PCL (B) and varying speed (F, 
revolution per minute, rpm) were significant negative effect on the EE and identified as the significant 
factor determining the EE of the microspheres. The microspheres showed high % EE (31.18 % to 96.81 %). 
The microspheres were found to be discrete, oval with porous surface. The FTIR analysis confirmed no 
interaction of KFN with the polymer. The XRPD revealed the dispersion of drug within microspheres 
formulation. Sustained drug release profile over 12 h was achieved by PCL polymer. In conclusion, 
polymeric microspheres containing KFN can be successfully prepared using the technique of experimental 
design, and these results helped in finding the optimum formulation variables for EE of microspheres.  
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Introduction 
Microspheres are well accepted system to control the drug release from the dosage form to improve 
bioavailability; it reduces absorption difference in patients, and dosing frequency as well as adverse effects 
during prolonged treatment [1]. Ketoprofen (KFN) is an NSAID having prominent anti-inflammatory, 
analgesic and antipyretic properties. KFN is an arylpropionic acid derivative and it is one of the most 
powerful inhibitors of cyclooxygenase at concentrations well within the range of therapeutic plasma 
concentration (EC50 2μg/l), which is resulting in a reduction in the tissue production of prostaglandins such 
as PGE2 and PGF2a [2]. In addition to its effect on cyclooxygenase, KFN inhibits the lipoxygenase pathway 
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of the arachidonic acid cascade. KFN is also a strongest inhibitor of bradykinin, an important chemical 
mediator of pain and inflammation. It also stabilizes lysosomal membranes against osmotic change and 
prevents the release of lysosomal enzymes that mediate tissue destruction in inflammatory react ions [3]. 
The half-life of KFN in plasma is about 2–2.5 hours. Due to its short half-life, KFN is a very good candidate 
for the formulation of sustained release dosage forms [2-3]. It is BCS II drug [4], KFN has low water 
solubility and exposure to the stomach at high levels can cause severe gastric damage such as ulceration or 
bleeding. To overcome these disadvantages, sustained release dosage forms have been developed, 
resulting in less frequent dosing and less GI disturbances [5].  
The solvent evaporation technique which was used in this study is a simple process that is also 
inexpensive enough for scaling up to a commercial level. The purpose of the present study was to prepare 
KFN microspheres by using solvent evaporation method and to study the effect of drug-polymer 
concentration on drug release. The main objective of this work was to investigate the possibility of getting 
sustained release KFN microspheres by the solvent evaporation method using polycaprolactone (PCL). 
Investigation of the effect of various processing and formulation factors such as drug to polymer ratio, 
stirring speed, surfactant concentration and others on the, yield, encapsulation efficiency (EE), and in-vitro 
release rate of drug from the microspheres were performed. 
Materials and Methods 
Materials 
Ketoprofen (KFN) was procured from Swapnroop Drugs and Pharmaceuticals (Aurangabad, India). 
Polycaprolactone (PCL- mw 70,000) was purchased from Sigma – Aldrich Chemicals India Pvt. Ltd. 
(Mumbai, India). n-Hexane and Dichloromethane (DCM) was procured from Merck Specialities Pvt. Ltd. 
(Mumbai, India). Polyvinyl alcohol (PVA- Mw 140, 000) was procured from HiMedia Laboratories Pvt. Ltd. 
(Mumbai, India). All other solvents and reagents were of analytical grade and used as provided. 
Methods 
Plackett–Burman design (PBD) 
The PBD factorial design of experiment was performed using Design-Expert® (DoE) software (Version- 
9.0.3.1, Stat-Ease Inc., Minneapolis, MN) [6-10]. In PBD, eleven numbers of lowest factors and forty seven 
numbers of highest factors can be used. In lowest eleven factors, five formulation factors and one process 
factor was investigated in order to enhance the EE of the microspheres and remaining five factors was 
dummied. PBD plotted twelve runs containing variation value of factors. Six independent variables such as 
amount of KFN drug (A, mg), PCL (B, mg), DCM (C, ml), Water (D, ml), Surfactant (E, % w/v) and Speed (F, 
revolution per minute, rpm). The level of screening variables evaluated in this study is listed in Table 1. DoE 
analyses the input data, presents the rank ordering of the variables, and designates the sign to the effect to 
indicate whether an increase in factor value was advantageous or not [11-13]. DoE shows, formulation 
equations, ANOVA for EE and drug loading (DL), p-value, F-value, mean square and R2 value. It also shows 
Pareto chart, experimental, predicted, and % prediction error values. The significance of the design was 
determined by the comparisons of statistical parameters, and on the basis of higher values of R2. Two-
dimensional (2D) contour plots and three-dimensional (3D) response plots resulting from the equations 
were constructed using Design- Expert® software. 
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Table 1. Screening variables and their levels in the Plackett-Burman Design 
Factor Name Unit Low Actual High Actual 
A KETOPROFEN mg 100 200 
B PCL mg 100 400 
C DCM ml 20 30 
D WATER ml 70 100 
E PVA mg 0.1 0.3 
F SPEED rpm 700 1000 
G G - -1 1 
H H - -1 1 
J J - -1 1 
K K - -1 1 
L L - -1 1 
Preparation of encapsulated microspheres 
KFN loaded microspheres were prepared using oil-in-water (O/W) single emulsion solvent 
evaporation method. An accurate weighed quantity of A (KFN), B (PCL) was mixed with a C (DCM) 
organic solvent as per the design. The resulting oil phase was injected drop wise using a syringe 
with a 21.5 G needle into a factor D (distilled water) as an external phase with stirring speed 
700/1000 rpm using lab stirrer (Remi electrotechnik limited, Thane, India) in a room temperature 
containing varying concentrations of PVA (factor E) as an emulsifier to produce an O/W single 
emulsion. After 60 min, n-hexane was added into the solution for hardening of the microspheres. 
Fig. 1 shows the schematic representation of formulation of KFN microspheres. Stirring was 
continued further at a varying speed 700/1000 rpm until the evaporation of organic solvent from 
solid microspheres. The microsphere were collected by filtration using vacuum filtration (Tid -15, 
Temp. 55 °C, Speed 1440 rpm) washed with n-Hexane, air dried for 48 h in room temperature and 
was used for further studies [6,14]. 
Characterization of the microspheres 
Encapsulation efficiency (% EE) 
The amount of KFN encapsulated into microsphere was determined by UV–vis spectrophotometer 
(HITACHI U-2900, Tokyo, Japan). An accurately weighed 10 mg of microspheres were stirred with 
dichloromethane (5 ml) to dissolve the polymer as well as drug and extracted in phosphate buffer solution 
pH 6.8 (up to 100 ml). Stirring was continued for 30 min at room temperature to facilitate the evaporation 
of organic solvent. The dispersion was filtered, and the residue was washed with phosphate buffer 
solution. The drug content was determined in the filtrate after appropriate dilution with a phosphate 
buffer solution at 260 nm using UV-vis spectrophotometer. The EE was expressed as the percentage of 
drug incorporated in the formulation relative to the total amount of drug (theoretical quantity) used in the 
formulation [6]. The % EE of KFN was calculated using the following equations: 
Drug entrapment efficiency (% ) = (actual drug content/theoretical drug content) x 100                    (1) 
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Figure 1. Schematic representation of formulation of KFN microspheres 
 
Among all twelve run formulations of microspheres having higher encapsulation efficiency were chosen 
for further characterization study. 
Scanning electron microscopy 
The morphology of microspheres was investigated by scanning electron microscopy (FESEM-S 4800, 
Hitachi, Japan) at a working distance of 8.0–8.9 mm and accelerating voltage of 15.0 kV. The particles were 
examined for shape, size and surface characteristics. For the morphology study, microsphere were 
mounted on metal stub using double sided adhesive tape and coated with gold for 80 second under 
vacuum. 
Fourier Transform Infrared (FTIR) spectroscopy study 
The chemical structure of the KFN, PCL and drug loaded microspheres were analysed using FTIR 
spectrophotometer (FTIR-8400, Shimadzu, Asia Pacific Pvt. Ltd. Singapore) by KBr pellet method. Sample (1 
mg) was mixed with KBr (40 mg) and formed into a disk by applying force in a manual press. Spectra were 
recorded in the scan range of 4000–400 cm−1. 
X-ray diffraction (XRD) 
X-ray diffraction patterns of KFN, PCL and drug loaded microspheres were obtained in X-ray 
diffractometer (Bruker, D8 Advanced, Germany) with Cu Kα radiation (λ = 1.5406 Ǻ). The samples were 
analysed over the angle range (2θ) 10°–80°. 
Differential scanning calorimetriy(DSC) 
Thermal behaviour of the sample KFN, PCL and drug loaded microsphere was determined by Differential 
Scanning Calorimetric (DSC-60, Shimadzu). Accurately weighed samples (5-10 mg) were sealed in an 
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aluminium pan and scanned at a temperature range of 30 °C to 400 °C at the rate of 10 °C/min under dry 
nitrogen atmosphere purge of 50 mL/min. 
In vitro drug dissolution studies 
Drug release from microspheres was performed in vitro using phosphate buffer (pH 6.8) for 12 h in 
Dissolution test App. (model FC 6X12R Electrolab TDT — 08 L, India) USPXXVIII, type-I with speed 100 rpm 
and temperature 37 ± 0.5 °C. The dissolution medium of phosphate buffer (pH 6.8) was prepared according 
to Indian Pharmacopoeia 2007 [15]. From 900 ml phosphate buffer i.e. dissolution medium 10 ml were 
withdrawn at predetermined time intervals and replenished with same volume of fresh dissolution media 
to maintain the sink condition. The samples were filtered through a Whatman filter paper no. 41. The KFN 
content of each sample after suitable dilution was assayed by UV spectroscopy at λ max of 260 nm using a 
1 cm cell. 
Result and Discussion 
Statistical design and analysis 
The PBD is an efficient approach to evaluate the results which are shown in Table 2. Design 
shows the formulation equation of % EE can be represented by the following equation: 
 
EE = +84.08-0.051A-3.02B+5.15C+7.34D+6.01E–2.85F-8.57G-7.71H+1.64J-6.21L                                  (2) 
 
Table 2. The Plackett-Burman Experimental Design matrix (in coded level) and experimental results 
Runs Variables Response 
 A B C D E F G H J K L EE, % 
1 1 -1 1 -1 -1 -1 1 1 1 -1 1 65.31± 0.56 
2 -1 1 1 1 -1 1 1 -1 1 -1 -1 96.81± 1.59 
3 -1 -1 1 -1 1 -1 1 1 -1 1 -1 91.86± 2.74 
4 1 -1 -1 -1 1 -1 1 -1 1 1 -1 95.04± 2.12 
5 -1 1 -1 -1 -1 1 1 1 -1 1 1 96.20± 1.25 
6 -1 -1 -1 -1 1 1 -1 1 1 -1 1 87.79± 2.55 
7 1 1 1 -1 1 1 -1 1 -1 -1 -1 94.66± 0.57 
8 1 1 -1 -1 1 -1 1 -1 -1 -1 1 80.27± 2.43 
9 1 1 -1 -1 -1 -1 -1 1 1 1 -1 93.24± 1.86 
10 -1 1 1 -1 1 -1 -1 -1 1 1 1 31.18± 0.94 
11 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 92.34± 0.83 
12 1 -1 1 -1 -1 1 -1 1 -1 1 1 84.31± 2.24 
 
From the above equation it is observed that the EE increased by the water (D), PVA (E), and 
followed by the dummy factors; (G), (H), (L). Dummy factors (G) and (H) have higher and 
significant effects on EE in the microspheres preparation process. Table 3 shows the design of 
ANOVA for encapsulation efficiency, p-value, F-value, mean square and R2 of the model. From the 
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ANOVA of PBD for drug loading, p-value, F-value, mean square and R2 of the model are given in 
the Table 4. Standardized Pareto chart of EE is shown in Fig. 2A and DL in Fig. 2B. Pareto charts 
showed that the parametrical graph containing the t-value of the student's t-test represents bars 
with a length proportional to the absolute value of the estimated effects divided by the standard 
error. There are eleven factors in which water (factor D), PVA (factor E) and Dummy factor G 
(Unknown in the process) has a significant influence on the EE. 
Table 3. Analysis of Variance for Encapsulation Efficiency (EE) 








Model 3695.00  101 369.50 1.55 0.5589(NS) 
A 0.031 1 0.031 1.30 0.9927 
B 109.51 1 109.51 0.46 0.6204 
C 318.37 1 318.37 1.34 0.4537 
D 646.36 1 646.36 2.72 0.3471 
E 432.84 1 432.84 1.82 0.4060 
F 97.41 1 97.41 0.41 0.6375 
G 881.17 1 881.17 3.71 0.3050 
H 713.48 1 713.48 3.00 0.3333 
J 32.44 1 32.44 0.14 0.7747 
L 463.39 1 463.39 1.95 0.3957 
Residual 237.72 1 237.72 - - 
Cor Total 3932.72 11 - - - 
d.f. = degree of freedom, S = significant, NS = non-significant. 
Standard deviation of the residual = 15.42. Correlation coefficient = 0.9396. 
 
Table 4.  Analysis of Variance for Drug loading (DL). 








Model 5554.80 10 555.48 152.10 0.0630(NS) 
A 978.85 1 978.85 268.03 0.03889(S) 
B 872.11 1 872.11 238.80 0.0411(S) 
C 84.48 1 84.48 23.13 0.1305 
D 760.98 1 760.98 208.37 0.0440(S) 
E 152.08 1 152.08 41.64 0.0979 
F 438.26 1 438.26 120.01 0.0580 
G 673.50 1 673.50 184.42 0.0468(S) 
H 24.25 1 24.25 6.64 0.2356 
J 1282.16 1 1282.16 351.08 0.0339(S) 
L 288.12 1 288.12 78.89 0.0714 
Residual 3.65 1 3.65 - - 
Cor Total 5558.45 11 - - - 
d.f. = degree of freedom, S = significant, NS = non-significant. 
Standard deviation of the residual = 1.91. Correlation coefficient = 0.9993. 
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Figure 2. (A) Pareto chart of % EE. (B) Pareto chart of % DL. (C) Encapsulation efficiency between actual and 
predicted values plot. (D) Encapsulation efficiency between residuals and run plot. (E)  Drug loading, 
between actual and predicted values plot. (F) Drug loading between residuals and run plot. 
 
It was found that the KFN (A), PCL (B) and Speed (F) had a significant negative effect on the % EE. The 
experimental, predicted, and % prediction error values for all the experimental runs are listed in Table 5 for 
EE and Table 6 for the DL. Therefore, it can be concluded that the model is best suitable because of the 
difference between experimental and predicted value, and % prediction error value is very low in Fig. 2 (C 
and D) for EE and (E and F) for DL. The desirability plot indicating desirable regression ranges for optimal 
process variable and the overlay plot indicating the region of optimal process variables are presented in 
Fig. 3 (A and B) [6-7]. PBD also showed the equation of % DL which is represented by the following 
equation: 
 
DL=+77.00-9.03A+8.52B+2.65C+7.96D-3.56E-6.04F-7.49G+1.42H-10.34J+4.90L                                   (3) 
 
The above equation 3 shows that out of eleven factors, DL increased by the factors; (A), (B), (D) and 
followed by the dummy factors; (G), (J). Dummy factor (J) and (A) has higher and significant effect on drug 
loading in the microspheres preparation process. It was found that the factors; (A), (E), (F), (G) and (J) had a 
significant negative effect on the % drug loading. 
Characterization of microspheres 
Encapsulation efficiency (% E.E) 
The EE of different experimental runs of the microspheres is reported in Table 2. The 3D response 
surface plots are useful in understanding about the main and interaction effects of the independent 
variables, whereas 2D contour plot gives a visual representation of values of the response [16]. To visualize 
the effect of independent variables on each response, 3D response surface plots & 2D contour plots (Fig. 4) 
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were constructed. Fig. 4B shows the effects of factor G and H on the response because both factors had 
more significant effect as compared to others. Contour plots and surface response plots (Fig. 4A & B) 
represented the increase in % EE while (Fig. 4C & D) represents contour plots and surface response plots of 
% DL respectively. Fig. 4D shows the effect of factor J and A on the response because both factors had 
more significant effect as compared to others. It was found that the KFN (A), PCL (B) and Speed (F) had a 
significant negative effect on the % EE. The % EE of the microspheres was ranged from 31.18 % to 96.81 %. 
 
Table 5. Experimental and Predicted value of the response EE. 
Run Experimental value Predicted Value Residual % Prediction eroor
 
1 65.31 60.86 4.45 6.81 
2 96.81 92.36 4.45 4.60 
3 91.86 87.41 4.45 4.84 
4 95.04 99.49 -4.45 -4.68 
5 96.20 91.75 4.45 4.62 
6 87.79 83.34 4.45 5.06 
7 94.66 99.11 -4.45 -4.70 
8 80.27 84.72 -4.45 -5.54 
9 93.24 88.79 4.45 4.77 
10 31.18 35.63 -4.45 -14.2 
11 92.34 96.79 -4.45 -4.81 
12 84.31 88.76 -4.45 -5.27 
Percent prediction error was calculated using the formula (experimental value − predicted 
value)/experimental value × 100. 
 
 
Table 6. Experimental and Predicted value of the response DL. 
Run Experimental value Predicted value Residual % Prediction error
 
1 52.78 52.33 0.55 0.85 
2 88.55 88.00 0.55 0.62 
3 76.48 75.93 0.55 0.71 
4 91.81 92.36 -0.55 -0.59 
5 79.09 78.54 0.55 0.69 
6 91.16 90.61 0.55 0.60 
7 88.33 88.88 -0.55 -0.62 
8 14.52 15.07 -0.55 -3.78 
9 77.24 76.69 0.55 0.71 
10 90.07 90.62 -0.55 -0.61 
11 89.42 89.97 -0.55 -0.615 
12 84.53 85.08 -0.55 -0.65 
Percent prediction error was calculated using the formula (experimental value − predicted 
value)/experimental value × 100. 
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Figure 3. (A) Desirability plot. (B) Overlay plot. 
 
 
Figure 4. (A) % EE contour plot, (B) % EE Response surface, (C) % DL contour plot, (D) % DL Response surface 
Scanning Electron Microscopy (FE-SEM) 
Shape, size and surface morphology of the KFN loaded microspheres were examined by FE SEM. 
Scanning electron microphotographs of microspheres prepared in this study are shown in Fig. 5. The size of 
microspheres was found to be in the range of 20 μm to 293 μm (Fig. 5d) and the microspheres are oval in 
shape with porosity and rough surface (Fig. 5c and d). 
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Figure 5. SEM micrographs and surface of KFN microspheres 
Fourier Transform infrared (FTIR) spectroscopy study  
 FTIR spectra were obtained in order to analyse the prepared microspheres. Fig. 6 shows typical spectra 
of pure KFN, polymers and encapsulated KFN in the microspheres. In the spectrum of KFN (A), principal 
peaks were found at 3288 cm
−1
 of N-H stretching, at 1654 cm
−1
 of C=C stretching, at 3055 cm−1 attributed 
to C-H stretching of the aromatic ring, at 2937 cm−1 attributed to aliphatic C-H stretching vibrations, at 
1076 cm−1 because of C-O C stretching, at 2978 cm−1 of ethoxy group stretching. In the spectra of PCL (B), 
principal peak at 3758 cm−1 of O-H stretching. The small peak at 2969 cm−1 corresponds to a symmetric 
structure vibration of the ethoxy groups, at 757 cm−1 of C-Cl stretching, at 1070 cm−1 of C-O-C stretching, at 
1387 cm−1 of O-H stretching, at 1763 cm−1 of carbonyl group stretching, These values remained very close 
in the FTIR spectra of optimized KFN loaded microspheres (C), indicating no existence of the interaction 
between the KFN and polymer. 
X-ray diffraction (XRD) 
The presence of numerous distinct peaks in the XRD patterns shown in Fig. 7 of KFN (A), at 2θ; 5.41°, 
12.28°, 13.52°, 15.34°, 16.08°, 16.43°,17.54° and 18.23° was present as crystalline material 88.2 % and 11.8 
% amorphous. There was no clear peak in the XRD patterns (B) of PCL indicate the amorphous nature of 
the polymer, crystalline 44.2 % and amorphous 55.8 %. The XRD patterns of drug loaded optimize 
formulation (C) crystalline 58.9 % and amorphous 41.1 % were characterized by the absence of distinct 
diffraction peaks of KFN, signifying a drug amorphization. Thus, XRD analysis suggested that the degree of 
crystallinity of KFN was reduced in the microspheres formulation, and most of the drug distributed in the 
polymer at molecular level. 
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Figure 6. (a) FTIR spectra of KFN, (b) PCL, (c) Microspheres 
Differential Scanning Calorimetry (DSC) 
DSC was carried out to find possible interaction between the drug and polymer. This was performed for 
pure drug (A), pure polymer (B) and drug loaded microspheres (C) using a differential scanning calorimeter 
(DSC- 60, Shimadzu). (Fig. 8) confirms that there was no interaction between drug and polymer. 
 
 
Figure 7. (A) XRD spectra of KFN, (B) PCL, (C) Microspheres 
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Figure 8. (A) DSC spectra of KFN, (B) PCL, (C) Microspheres 
In vitro drug dissolution studies 
PCL is water insoluble degradable polymer and able to control drug release from microspheres. Fig. 9 
shows the cumulative % drug release as a function of the dissolution time from the KFN loaded 
microspheres. The release of KFN was evaluated using phosphate buffer (pH 6.8) as the release media. 




Figure 9. Cumulative % drug release 
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Conclusions 
This work shows KFN loaded PCL polymeric microspheres were successfully prepared. Effects of various 
independent formulation or process variables and dependent variables had been screened out by 
employing PBD screening design. The mathematical model for the response developed using statistical 
analysis quantitatively describes the influence of the selected variables on the responses under study. The 
% EE of the microspheres was ranged from 31.18% to 96.81%. The size of microspheres was found to be in 
the range of 20 μm to 293 μm was confirmed by SEM analysis. The absence of drug polymer interactions 
was confirmed by FTIR spectroscopy and DSC. The XRPD showed the distribution of drug in the polymer at 
molecular level. Drug release from microspheres showed a sustained release i.e. 14.52 % – 91.81 % over a 
period of 12 h in a phosphate buffer (pH 6.8). Microspheres prepared by such methods may represent a 
promising approach for efficient encapsulation and sustained drug release of KFN.  
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